Table 3. . Recurrent anaplastic astrocytoma trials.
| Study (year) | Trial design | Patient number | Overall response rate (%) | Median progression-free survival (months) | 6-month progression-free survival (%) | Median overall survival (months) | Ref. |
|---|---|---|---|---|---|---|---|
| Wong et al. (1999) | Phase II (total of 8) | 150 | 14 | 3.25 | 31 | 7.5 | [68] |
| Lamborn et al. (2008) | Phase II (total of 12) | 159 | 7 | 6 | 28 | 8 | [69] |
| Yung et al. (1999) | Randomized Phase III | 162 (AA/AOA) | 35 | 5.4 | 46 | 13.6 | [70] |
| Bevacizumab trials | Retrospective and prospective (total of 8) | 258 (65% AG) | 24–64 | 2.9–7.0 | 21–60 | 11–16 | [71,72] |
| Chamberlain (2015) | Retrospective | 35 | 5.7 | 4.5 | 40 | 9.5 | [73] |
AA: Anaplastic astrocytoma; AOA: Anaplastic oligodendroglioma; AG: Anaplastic glioma.